Weixinkang Subsidiary Obtains Drug Registration Certificate for Compound Potassium Phosphate Injection

Regulation
โดย CLS·Read original
Summary · why it matters

Weixinkang announced that its wholly-owned subsidiary Baiyi Pharmaceutical has received the drug registration certificate for Compound Potassium Phosphate Injection approved and issued by the National Medical Products Administration. The drug was first approved in the United States in 1983 for correcting hypophosphatemia and parenteral nutrition support, and is currently marketed in countries including Canada. The original reference listed drug has not been launched in China.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 1

白医制药Private▲ Positive
Regulationrelevance

Baiyi Pharmaceutical received drug registration certificate for Compound Potassium Phosphate Injection.

© 2026 MarketDXNews